Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 3/20 | 0.54 |
| ▸ | TDO2 | P48775 | 5/20 | 0.53 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16735236 | 0.81 | RAF1 (0.66) | BRAFKDRLCKTEKRAF1 | |
| SCHEMBL30402032 | 0.81 | RAF1 (0.66) | BRAFKDRLCKTEKRAF1 | |
| SCHEMBL15169397 | 0.80 | ALDH1A1 (0.58) | RAF1TDO2RIPK1EGFRAURKA | |
| SCHEMBL2265817 | 0.79 | BRAF (0.58) | BRAFKDRLCKTEKTDO2 | |
| SCHEMBL29638626 | 0.79 | BRAF (0.58) | BRAFKDRLCKTEKTDO2 | |
| SCHEMBL15068524 | 0.77 | RAF1 (0.58) | RAF1PDGFRB | |
| SCHEMBL16237840 | 0.74 | TDO2 (0.75) | TDO2RAPGEF4 | |
| SCHEMBL2261398 | 0.74 | BRAF (0.58) | BRAFKDRLCKTEKRAF1 | |
| SCHEMBL15066901 | 0.73 | BRAF (0.49) | BRAFKDRLCKTEKRAF1 | |
| SCHEMBL2264176 | 0.72 | TEK (1.00) | BRAFKDRLCKTEKRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797927-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013100632-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | BRAF 1/4885KDR 700/4885LCK 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.